| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate |
2018-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-109266747-B |
| titleOfInvention |
GPR56 related to I-type neurofibroma complicated with spinal malformation and application thereof |
| abstract |
The invention discloses application of GPR56 as a marker in preparation of a product for detecting I-type neurofibroma complicated with spinal malformation. According to the invention, a marker GPR56 related to I-type neurofibroma combined with spinal malformation is screened by a transcriptome sequencing technology, so that the effect of GPR56 in the occurrence and development of I-type neurofibroma combined with spinal malformation bone healing defects and the acting mechanism of GPR56 are proved, GPR56 is used as a novel NF1 combined spinal malformation biomarker, and an important theoretical basis is provided for guiding clinical early intervention and targeted therapy of GPR 3526. |
| priorityDate |
2018-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |